- Home
- REVBW vs HOFT Comparison
REVBW vs HOFT Comparison
Compare REVBW & HOFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- HOFT
- Stock Information
- Founded
- REVBW N/A
- HOFT 1924
- Country
- REVBW United States
- HOFT United States
- Employees
- REVBW 9
- HOFT N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- HOFT Home Furnishings
- Sector
- REVBW Health Care
- HOFT Consumer Discretionary
- Exchange
- REVBW Nasdaq
- HOFT Nasdaq
- Market Cap
- REVBW N/A
- HOFT N/A
- IPO Year
- REVBW 2020
- HOFT 1999
- Fundamental
- Price
- REVBW $0.01
- HOFT $17.83
- Analyst Decision
- REVBW
- HOFT
- Analyst Count
- REVBW 0
- HOFT 0
- Target Price
- REVBW N/A
- HOFT N/A
- AVG Volume (30 Days)
- REVBW N/A
- HOFT 23.3K
- Earning Date
- REVBW N/A
- HOFT 12-05-2024
- Dividend Yield
- REVBW N/A
- HOFT 5.16%
- EPS Growth
- REVBW N/A
- HOFT N/A
- EPS
- REVBW N/A
- HOFT 0.12
- Revenue
- REVBW N/A
- HOFT $402,257,000.00
- Revenue This Year
- REVBW N/A
- HOFT N/A
- Revenue Next Year
- REVBW N/A
- HOFT $17.87
- P/E Ratio
- REVBW N/A
- HOFT $152.63
- Revenue Growth
- REVBW N/A
- HOFT N/A
- 52 Week Low
- REVBW N/A
- HOFT $13.09
- 52 Week High
- REVBW N/A
- HOFT $27.15
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- HOFT 54.37
- Support Level
- REVBW N/A
- HOFT $17.83
- Resistance Level
- REVBW N/A
- HOFT $19.41
- Average True Range (ATR)
- REVBW 0.00
- HOFT 0.87
- MACD
- REVBW 0.00
- HOFT 0.10
- Stochastic Oscillator
- REVBW 0.00
- HOFT 54.07
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).